Ruti Aga's six-year ban: two years for the injection, four for a prescription no clinic ever issued

Ruti Aga won a half marathon in China in March, gave a sample, and what the Athletics Integrity Unit's Thursday statement leads with is not a drug but a document. The knee-treatment prescription carried the stamp of a clinic that does not exist; the person who wrote it was a family member with no medical registration; and when questioned, that person said it had been written on an old pad from a former workplace — which the workplace has explicitly disowned. Three independent verification points, three failures.

The arithmetic in the statement is plain: two years for the presence violation, four for tampering, six in total, running from 10 September. The provisional suspension also dates from 10 September, so the clock started the day she was first stopped. That is procedural bookkeeping, not a discount.

I went back to the 2026 Berlin sheet before writing a word on this case. To price a loss you need a baseline, and that baseline was laid down in Berlin, not on 10 September.

Context: what is in the record, and what the record is missing

Aga is 32. My own marathon sheet carries two entries for her — Berlin 2026, roughly 2:18:34, second place; Tokyo 2026, roughly 2:20:40, first. Those figures come from my notes and are still pending a cross-check against official splits, so I use them as a baseline rather than a claim. Add three second-place finishes at World Marathon Majors. That is a Major-tier record, not a championship-tier one; there is no global championship medal beside her name.

The race itself has no mark attached to it anywhere in the statement. No time for the Chinese half marathon, no splits, no field description. The implication is straightforward: any performance judgement would be invented data. What survives is that she won it, which tells you the field was elite, the testing was in-competition, and the road-race testing window — open from 23:59 the day before the race — had already caught her. The knee injection fell inside that window, not outside it.

There is an empty column in the archive here. The disqualification scope is unstated: whether the March result and its prize money are voided. Standard AIU practice disqualifies the competition at which the sample was collected, but the line is not in the text. The years of the March race and the ban start are also unstated. There is no Ethiopian federation statement; only the AIU is quoted. Whether the agent or management that accepted the document was investigated is unknown.

Core: the substance class, the sanction arithmetic and the document chain

Start with the technical error that has been repeated across coverage. Methylprednisolone has been described as a prohibited steroid. That is imprecise. Methylprednisolone is a glucocorticoid — WADA Prohibited List class S9 — not an anabolic steroid (S1). Under the current List, S9 glucocorticoids are prohibited in-competition only, by injection, oral or rectal routes. The case therefore turns on route and timing, not on steroid use. A therapeutic knee injection out of competition is entirely legal; it becomes a violation only if residues are present in competition.

That distinction is the legal hinge and the only viable defence. Intra-articular methylprednisolone for knee synovitis is standard sports medicine in distance runners. That plausibility is precisely what made the forgery fatal: a genuine treatment would have been defended with genuine records, not manufactured ones. The easiest legitimacy in the case to prove was the one destroyed.

Now the sanction arithmetic, because it cannot be understood without counting. Two years for presence, four for tampering. The structure reads cleanly: the presence charge was treated as a Specified Substance finding without proven intent — hence the standard two years — and the tampering as fully culpable, at the Code's standard four. The most important part of the sum is what is missing from it: the panel declined the no-significant-fault mitigation. With that mitigation, the presence element could have come down from two years, and the tampering charge would not have existed at all.

The tampering charge did not come from the paper alone. The language of the statement indicates it also rests on statements made in the investigative interview — the account given in questioning collided with the documents. Language and translation conditions in AIU interviews with distance runners have been a recurring point of contention; this case does not settle that argument, it adds an entry to it.

The document chain had three independent points at which it could have held, and it failed at all three. The clinic does not exist. The practitioner was an unregistered family member. The pad was disowned by the institution it was said to come from. One surviving truth at any one of those points would have taken half the charge down with it.

The governance gap is larger than the sanction

What is missing here is not medicine but medical structure. A credentialed team physician would have created a record of the injection; a record would have meant a TUE application or adherence to a route-specific washout period; and either route would have made a forged prescription unnecessary. The moment a family member writes a prescription as a doctor, it is clear that no professional medical apparatus existed around the athlete.

The knee is the root cause, and it reads as systemic rather than individual. Chronic knee pathology is a known load-bearing failure mode in high-volume marathoners. At elite level, an injured runner faces pressure to protect appearance-fee income, and the cheapest, most available tool for masking that pain is a glucocorticoid. The forgery sits downstream of the governance gap, not upstream of it.

Contrarian: six years of sanction, six weeks of headline

Two doubts have to be kept separate, because merging them is the fastest way to misread the case.

The first doubt is about the document, and it is fair. Forging the prescription was the athlete's own decision; no institutional conspiracy produced it, and four of the six years attach to that act. The AIU's conduct here is severe and correct in its own terms: the enforcement frontier has shifted from what is in the sample to whether the paperwork is real, and that shift matters for a road-racing era of denser in-competition testing.

The second doubt is about the substance, and it is also fair. Six years for a substance with no proven endurance benefit is a number that will be quoted from both directions. One camp will call it proof of AIU rigour; another will call it evidence of disproportionate enforcement against African road runners. The fact is that four of the six years were bought by the paper, not the drug — and that arithmetic would apply identically to a Kenyan, a European or an Indian road runner.

The comparison that has already broken is the one the media built by calling the substance an anabolic steroid. An anabolic case turns on what was taken; a glucocorticoid case turns on when and by which route. The first presumes intent; the second is decided by a timetable. Change the category and you change both the available defence and the reader's understanding.

Print fifth and sixth place too

One athlete leaving the event does not alter Ethiopian women's marathon depth. There is a sub-2:16 cohort ahead of her, and a 2:18–2:20 runner is not automatically selectable. The ban's effect on medal capacity is nil; its deterrent effect is strongest at the tier where sanction and income collide in the same race. That is the tier China's label circuit occupies — large appearance-fee budgets, deep East African fields, and now the AIU's highest-yield testing ground.

So when the next person says one case sets a trend, remember that one case is a question, not a trend. The question is whether this ends at athlete level or reaches the entourage. The statement says a family member wrote the prescription. It does not say whether an agent accepted it — and that empty column is the most important part of the file.

Forward

The CAS appeal window opens within roughly twenty-one days under the Code, but a document-based finding is hard to overturn, and here the document failed at three separate verification points. A return would come at about 38; at that age, in that depth of field, with a doping history, selection is not a debate.

The real watch is on whom the AIU charges next. If the coming twelve months produce cases where the forger, the team physician or the agent is also named, Aga's file becomes a date of change. If not, it remains a six-year sanction in which the paper carries the weight and the athlete pays the price. My sheet carries one line on it: presence two years, tampering four, and the fifth column is blank — which is the story.